These guides are AI-generated educational summaries — not legal or medical advice.
C&P Exam Prep: Benign Brain Tumor
DBQ Overview
Interview + Physical- Form Name
- Central_Nervous_System_and_Neuromuscular_Diseases
- Form Code
- Central_Nervous_System_and_Neuromuscular_Diseases
- Page Count
- 13
- Examiner Type
- Physician or Psychologist
- Estimated Duration
- 60-90 minutes
- Exam Format
- Interview + Physical
What to Expect During Your Exam
Exam Overview
To document the current severity, nature, and functional impact of your service-connected or claimed benign brain tumor under DC 8003, including active disease status, residual neurological deficits, and treatment history, so that the VA rater can assign an accurate disability rating.
What the examiner evaluates:
- Tumor type, location, and benign versus malignant classification
- Current active disease status versus residual/post-treatment phase
- All neurological signs and symptoms attributable to the tumor or its treatment
- Motor function: strength, coordination, and fine motor control in all four extremities
- Sensory function: numbness, tingling, and altered sensation
- Cognitive function: memory, attention, concentration, and executive function
- Speech and communication: dysarthria, aphasia, or complete inability to communicate
- Gait, balance, and fall risk
- Bowel and bladder function: incontinence, hesitancy, retention, frequency
- Swallowing function and dysphagia severity
- Sleep disturbances including insomnia, hypersomnolence, or sleep apnea
- Visual disturbances or cranial nerve deficits
- Headache frequency, severity, and functional impact
- Seizure activity and frequency
- Treatment history: surgery, radiation, chemotherapy, and dates
- Assistive devices required: cane, walker, wheelchair, braces, crutches
- Muscle atrophy and its location
- Functional impact on activities of daily living and ability to work
- Pulmonary function if respiratory involvement is present
The exam will be conducted in person at a VA facility or contracted examiner office. You may have a VSO representative or trusted individual present. In most states you have the right to record the examination; notify the examiner before beginning. Bring all relevant imaging, operative reports, oncology records, and a written symptom summary.
Typical duration: 60-90 minutes
Motor Strength Testing (Manual Muscle Testing)
Muscle strength in upper and lower extremities bilaterally using the 0-5 scale; the examiner will test elbow flexion/extension, wrist flexion/extension, grip, pinch, knee extension, and ankle dorsiflexion/plantar flexion on both sides.
What to expect:
The examiner will ask you to push, pull, or resist movement against their hand. Testing is done with and without assistance. Results are recorded for right and left upper and lower extremities separately.
Key thresholds:
- 5/5 (normal) — No motor deficit documented; may reduce overall rating if all other findings are also normal.
- 4/5 (slight weakness) — Mild paresis; contributes to rating for slight incomplete paralysis of relevant peripheral nerve group.
- 3/5 (movement against gravity only) — Moderate paresis; supports moderate incomplete paralysis rating.
- 2/5 or less (cannot overcome gravity) — Severe paresis or complete paralysis; supports maximum rating for affected nerve group.
Tips:
- Perform testing on a typical or bad day, not your best possible day.
- If weakness is intermittent and worse with fatigue, tell the examiner this before testing begins.
- If you normally use an assistive device, bring it and use it during the exam.
- Report any pain, fatigue, or weakness that occurs during or after repeated movement.
- If your dominant hand is affected, clearly state this-it affects the rating.
Pain considerations: Pain during motor testing is relevant but motor strength ratings for a neurological condition are assessed independently of pain. Report both the pain level and how it limits your effort or affects your functional use of the extremity.
Reflex Testing (Deep Tendon Reflexes)
Integrity of motor pathways; the examiner will test biceps, triceps, brachioradialis, knee, and ankle reflexes bilaterally. Hyperreflexia may indicate upper motor neuron involvement from the brain tumor; hyporeflexia may indicate peripheral involvement.
What to expect:
A reflex hammer will be used at standard tendon sites. The examiner will compare side-to-side symmetry and note abnormalities such as clonus, spasticity, or absent reflexes.
Key thresholds:
- Hyperreflexia with clonus or spasticity — Indicates upper motor neuron damage consistent with active or residual brain tumor effect; supports higher rating.
- Absent or diminished reflexes — Indicates lower motor neuron or peripheral nerve involvement; documents objective neurological deficit.
Tips:
- Do not mask or suppress your natural reflex response; try to relax the limb completely.
- Tell the examiner if you have noticed spasms, tightness, or involuntary movements at home.
- Spasticity that is not present during the exam but occurs regularly at home must be verbally reported.
Pain considerations: Spasticity and hyperreflexia can cause painful muscle cramps. Describe the frequency and severity of any spasm-related pain.
Gait and Balance Assessment
Coordination, cerebellar function, proprioception, and risk of falls. The examiner may observe your normal gait, tandem gait (heel-to-toe), and Romberg testing (standing with eyes closed).
What to expect:
You will be asked to walk across the room normally, then heel-to-toe in a straight line. The examiner will observe for ataxia, foot drop, shuffling, wide-based gait, or need for assistive device. If gait is abnormal and you have multiple conditions, the examiner must document which condition contributes to the gait abnormality.
Key thresholds:
- Ataxic or wide-based gait — Objective evidence of cerebellar or vestibular dysfunction attributable to the brain tumor.
- Requires assistive device for ambulation — Documents functional limitation and supports Special Monthly Compensation (SMC) consideration.
- Unable to ambulate without assistance — Supports maximum rating and potential SMC-L consideration.
Tips:
- Use your assistive device during gait testing if you normally rely on it.
- If your gait is worse when tired or at the end of the day, tell the examiner this is a typical functional limitation.
- Report any recent falls, near-falls, or fear of falling that restricts your activities.
- If the examiner does not observe your worst-day gait, verbally describe it in detail.
Pain considerations: Balance problems caused by the brain tumor may cause anxiety, dizziness, or secondary musculoskeletal pain from compensatory posture. Report all associated symptoms.
Cognitive Screening
Memory, attention, concentration, and executive function. The examiner may use brief screening tools or refer to neuropsychological testing results. Cognitive deficits are a critical component of the functional impact section of the CNS DBQ.
What to expect:
The examiner may ask questions assessing orientation, short-term memory recall, serial subtraction, naming, and problem-solving. Formal neuropsychological testing may be separately arranged. Deficits here directly impact the functional impairment narrative.
Key thresholds:
- Mild cognitive impairment — Supports functional limitation documentation; contributes to overall rating through analogous codes.
- Moderate to severe cognitive impairment — Significantly increases overall disability rating; may support 100% rating or total disability if it prevents gainful employment.
Tips:
- Do not 'try harder' than usual-perform at your typical daily level.
- Report that cognitive symptoms fluctuate and are often worse with fatigue, stress, or illness.
- If you have had prior neuropsychological testing, bring results and dates.
- Describe how cognitive deficits affect your ability to work, manage finances, keep appointments, and maintain relationships.
Pain considerations: Cognitive fatigue after mental exertion is a valid and ratable symptom. Describe how cognitive effort leads to exhaustion that requires rest.
Speech Assessment
Intelligibility, articulation, fluency, and ability to communicate. The examiner will note dysarthria, aphasia, or complete inability to communicate by speech.
What to expect:
The examiner will evaluate your speech during the history-taking portion of the exam. If speech is abnormal, the type and severity will be described in detail. The DBQ distinguishes between unintelligible speech and inability to communicate.
Key thresholds:
- Unintelligible speech or aphonia — Potentially supports 100% rating for the speech manifestation alone.
- Constant inability to communicate by speech — Supports maximum rating and potential SMC consideration.
Tips:
- If your speech is worse when fatigued or stressed, schedule the exam at a time when this is more likely to manifest.
- Bring a family member or caregiver who can describe your speech impairment on typical bad days.
- If you use alternative communication devices, describe them to the examiner.
Pain considerations: Effort required to speak may cause fatigue or headache. Report this as a functional consequence of your condition.
Pulmonary Function Testing (Spirometry - FEV1, FVC, FEV1/FVC)
Respiratory muscle strength and lung capacity, relevant if your brain tumor or its treatment has caused respiratory compromise such as sleep apnea or chronic respiratory failure.
What to expect:
If pulmonary involvement is suspected, you will breathe into a spirometer. FEV1, FVC, and FEV1/FVC ratio are the key values recorded on the DBQ. Dates of testing must be documented.
Key thresholds:
- Sleep apnea requiring CPAP/BiPAP — Separately ratable at a minimum of 50% if requiring use of breathing assistance device.
- Chronic respiratory failure with carbon dioxide retention — Supports 100% rating for the respiratory manifestation.
Tips:
- If you use CPAP, BiPAP, or other breathing assistance, bring the device and prescription to the exam.
- Report any history of aspiration pneumonia, which can result from dysphagia associated with the brain tumor.
Pain considerations: Respiratory effort with neurological weakness can cause accessory muscle pain and fatigue. Report any chest discomfort or dyspnea on exertion.
Rating Criteria Breakdown
| Rating % | Criteria | Key Symptoms |
|---|---|---|
| 100% | DC 8003 - Benign Brain Tumor as active disease. Under 38 CFR 4.124a, DC 8003 provides for a 100% rating while the tumor is active. Under the analogous framework used for brain new growths (DC 8002/8003), active disease is rated at 100%. Note: For malignant brain tumors (DC 8002), VA policy concedes 100% for two years following cessation of treatment, and then residuals are rated. For benign tumors (DC 8003), the 100% applies during active disease; thereafter residuals are rated using analogous codes for the neurological manifestations present (e.g., paralysis, speech, cognitive, bowel/bladder). A minimum rating of 10% applies for any residuals. |
CFR: DC 8003 Brain, new growth of, benign: As active disease 100. Rate residuals under the appropriate diagnostic code with a minimum rating of 10. See also DC 8000 'Brain, new growth of' and DC 8002 for malignant analog. |
| 10% | Minimum residual rating after active disease phase resolves or following cessation of treatment. Under DC 8003, once active disease is no longer present, residuals must be rated using the appropriate analogous diagnostic code for each neurological manifestation. The floor is 10% for any documented residuals. Residuals are rated individually (e.g., incomplete paralysis, cognitive impairment, speech disorder, bowel/bladder dysfunction) and may combine to a higher overall evaluation under 38 CFR 4.25. |
CFR: 38 CFR 4.124a DC 8003: Rate residuals, minimum 10. Each residual is rated under the appropriate DC (e.g., DC 8007 for hemiplegia analogs, cranial nerve codes for speech/swallowing). Combine residual ratings using 38 CFR 4.25 combined ratings table. |
100% DC 8003 - Benign Brain Tumor as active disease. Under 38 CFR ...
DC 8003 - Benign Brain Tumor as active disease. Under 38 CFR 4.124a, DC 8003 provides for a 100% rating while the tumor is active. Under the analogous framework used for brain new growths (DC 8002/8003), active disease is rated at 100%. Note: For malignant brain tumors (DC 8002), VA policy concedes 100% for two years following cessation of treatment, and then residuals are rated. For benign tumors (DC 8003), the 100% applies during active disease; thereafter residuals are rated using analogous codes for the neurological manifestations present (e.g., paralysis, speech, cognitive, bowel/bladder). A minimum rating of 10% applies for any residuals.
Key Symptoms
- Active, untreated or currently treated benign brain tumor
- Ongoing surgery, radiation therapy, or chemotherapy
- Active neurological deterioration attributable to tumor mass effect
- Tumor confirmed by imaging (MRI/CT) as currently present and symptomatic
- Currently under active oncological or neurosurgical management
CFR: DC 8003 Brain, new growth of, benign: As active disease 100. Rate residuals under the appropriate diagnostic code with a minimum rating of 10. See also DC 8000 'Brain, new growth of' and DC 8002 for malignant analog.
10% Minimum residual rating after active disease phase resolves ...
Minimum residual rating after active disease phase resolves or following cessation of treatment. Under DC 8003, once active disease is no longer present, residuals must be rated using the appropriate analogous diagnostic code for each neurological manifestation. The floor is 10% for any documented residuals. Residuals are rated individually (e.g., incomplete paralysis, cognitive impairment, speech disorder, bowel/bladder dysfunction) and may combine to a higher overall evaluation under 38 CFR 4.25.
Key Symptoms
- Post-operative or post-radiation residual neurological deficits
- Mild motor weakness in one or more extremities
- Mild cognitive difficulties affecting daily function
- Mild speech impairment
- Mild bowel or bladder dysfunction
- Intermittent headaches with some functional limitation
- Persistent fatigue or sleep disturbance
CFR: 38 CFR 4.124a DC 8003: Rate residuals, minimum 10. Each residual is rated under the appropriate DC (e.g., DC 8007 for hemiplegia analogs, cranial nerve codes for speech/swallowing). Combine residual ratings using 38 CFR 4.25 combined ratings table.
How to Describe Your Symptoms
Active Disease Status and Treatment
How to describe:
Clearly state whether your tumor is currently active, under treatment, or in a surveillance/watchful-waiting phase. Provide exact dates of most recent surgery, radiation, and chemotherapy. If currently in active treatment, state this explicitly at the start of the exam-this is the key trigger for the 100% rating.
Worst-day example:
“I am currently receiving radiation therapy for my benign brain tumor. My most recent treatment was [date]. Even on what I would call a better day, I experience severe fatigue that keeps me in bed for most of the afternoon. On my worst days, which occur [X] times per week, I am unable to get out of bed, cannot perform basic self-care, and experience debilitating headaches rated 9 out of 10.”
What the examiner listens for:
Confirmation of active disease, current treatment modality, dates of most recent treatment, and whether treatment is ongoing or completed. The examiner needs to check whether this qualifies for the active-disease 100% rating versus the residuals rating framework.
Understatements to avoid:
Do not say 'I am doing okay' or 'things are improving' if you are still in active treatment or still experiencing significant symptoms. Do not volunteer that you are in remission unless specifically asked and confirmed by medical records.
Neurological Residuals - Motor Function
How to describe:
Describe exactly which limbs are affected, whether the weakness is constant or fluctuating, and how it limits specific daily activities. Specify whether your dominant hand is affected. Describe weakness, spasticity, tremor, incoordination, and any falls.
Worst-day example:
“On my worst days, which happen about three times a week, my right arm is so weak I cannot hold a coffee cup or button my shirt. I dropped my phone twice last week. My grip feels like it just gives out without warning. I have fallen twice in the past month because my right leg buckles.”
What the examiner listens for:
Objective correlation between reported weakness and manual muscle testing findings; side dominance; history of falls; functional limitations in ADLs; use of assistive devices; whether weakness is worse with fatigue or repetitive use.
Understatements to avoid:
Do not demonstrate your maximum capability during motor testing if it does not reflect your typical functional level. Do not say 'I manage okay' when describing activities that require significant compensation or workarounds.
Cognitive Impairment
How to describe:
Describe specific examples of memory failures, word-finding difficulties, inability to concentrate, poor decision-making, and how these affect your work, finances, and relationships. Give concrete examples with dates or frequency.
Worst-day example:
“On my worst days, I cannot remember a conversation I had an hour ago. I had to stop driving because I got lost three times going to places I have been to hundreds of times. I missed four medical appointments last month because I could not remember them even with reminders. I can no longer manage my own finances.”
What the examiner listens for:
Specific, concrete examples of cognitive failures rather than vague complaints; impact on employment and independent living; whether cognitive impairment is progressive; prior baseline cognitive functioning; whether neuropsychological testing has been performed.
Understatements to avoid:
Do not minimize cognitive difficulties by saying 'I just forget things sometimes.' Avoid performing better than your daily average during cognitive screening by trying harder than usual.
Headaches
How to describe:
Report frequency (how many days per week or month), severity (0-10 scale), duration, location, associated symptoms such as nausea or vision changes, and impact on function. Distinguish between typical headaches and severe incapacitating episodes.
Worst-day example:
“I get severe headaches at least four days a week. On the worst days, which occur about twice a week, the pain is a 9 out of 10, I cannot tolerate light or sound, I vomit, and I am completely non-functional for 6-8 hours. These prostrating headaches have caused me to miss work [X] days in the last month.”
What the examiner listens for:
Frequency of prostrating attacks with or without productive work loss; whether headaches are attributable to the brain tumor or its treatment; current medications and their effectiveness; whether headaches are separately ratable under DC 8100.
Understatements to avoid:
Do not say 'I just push through them' in a way that suggests they are not severely disabling. Do not forget to report the lost workdays or functional days caused by headaches.
Bowel and Bladder Dysfunction
How to describe:
Report each specific symptom: urinary frequency, hesitancy, incontinence (stress vs. urge), retention, slow stream, and any catheter use. For bowel: incontinence, constipation, need for bowel program, digital stimulation, absorbent material use, and frequency of accidents. Report how many times per day/night and whether absorbent materials are required.
Worst-day example:
“I wear absorbent underwear every day because I have urinary accidents at least three times a day and cannot always reach the bathroom in time. I also have bowel accidents approximately twice a week and require a bowel program every other day. I cannot go more than 90 minutes without trying to void.”
What the examiner listens for:
Frequency and severity of incontinence episodes; requirement for absorbent materials and how often they must be changed; use of catheters or bowel programs; impact on social activities and employment; whether symptoms are attributable to the brain tumor versus other causes.
Understatements to avoid:
Do not underreport bowel and bladder symptoms out of embarrassment. These are critical to the rating and directly affect which rating level is assigned. Do not say 'I handle it' if you are using absorbent materials, avoiding public places, or limiting activities because of bladder/bowel concerns.
Dysphagia and Speech Impairment
How to describe:
Describe difficulty swallowing solids versus liquids, coughing or choking during meals, need for dietary modifications, requirement for daily medication to control dysphagia, or esophageal stent placement. For speech, describe intelligibility, effort required to speak, and whether others understand you.
Worst-day example:
“I have been on a pureed diet for six months because I choke on anything solid. I take daily medication to help with swallowing. My speech becomes slurred when I am tired, and by the end of the day strangers cannot understand me. My family has started writing things down because they cannot always understand what I am saying.”
What the examiner listens for:
Whether dysphagia requires daily medication, esophageal stent, or PEG tube; whether aspiration has occurred; speech intelligibility during the exam; comparison of speech at the beginning versus end of the exam when fatigue sets in.
Understatements to avoid:
Do not say swallowing is 'fine' if you have modified your diet. Do not conduct the exam in the morning if your speech is worse in the evening-or if you do, describe this discrepancy explicitly.
Fatigue and Sleep Disturbance
How to describe:
Describe fatigue as a separate, disabling symptom from pain or weakness. Report daily onset time, duration, impact on activity level, and whether rest resolves it. For sleep: insomnia, hypersomnolence, daytime sleep attacks, and sleep apnea requiring CPAP/BiPAP. Note that these are specifically listed as separately rateable manifestations on the CNS DBQ.
Worst-day example:
“My fatigue is so severe that by noon I have to lie down for two to three hours just to function at a minimal level. I cannot complete any task that takes more than 30 minutes without needing to rest. I use a CPAP machine every night for sleep apnea diagnosed after my brain tumor. Even with CPAP, I still wake three to four times per night and feel unrefreshed every morning.”
What the examiner listens for:
Whether fatigue is disproportionate to exertion; daytime hypersomnolence; documented sleep study for sleep apnea; use of breathing assistance devices; whether fatigue limits productive activity to less than a half day; potential for separate rating under DC for sleep apnea.
Understatements to avoid:
Do not minimize fatigue by attributing it to age, stress, or laziness. Do not forget to mention CPAP use or sleep study results.
Common Mistakes to Avoid
Stating the tumor is 'gone' or 'removed' without clarifying residual status
After successful surgery or treatment, veterans sometimes say the tumor is 'gone,' which an examiner may interpret as no current disability. However, significant residuals from the tumor or its treatment remain fully ratable at a minimum of 10%, and at higher levels depending on their severity.
Instead: State clearly: 'The tumor was surgically removed on [date], but I have the following ongoing residual symptoms that persist and affect my daily functioning.' Then list each residual symptom in detail.
Impact: All post-treatment residual ratings (10% minimum and above)
Performing at your best rather than your typical functional level during the exam
The C&P exam is a snapshot. Veterans often unconsciously put their best foot forward, demonstrating capabilities that do not reflect their average or worst-day functioning. The VA is supposed to rate based on the overall picture of the condition, including bad days.
Instead: Before any physical or cognitive testing, tell the examiner: 'I want to note that today may not reflect my worst days. On bad days, which occur [X] times per week, I experience [specific limitations].' Then describe those limitations in detail.
Impact: All rating levels for motor, cognitive, and functional impairment
Failing to report all neurological symptoms because they seem unrelated to the brain
Many veterans do not realize that bowel dysfunction, bladder dysfunction, sexual dysfunction, swallowing difficulty, sleep apnea, and respiratory compromise can all be direct neurological residuals of a brain tumor or its treatment, and all are specifically addressed on the CNS DBQ.
Instead: Systematically review every system addressed on the CNS DBQ with your VSO or advocate before the exam. Report any symptom that began or worsened after the tumor diagnosis or treatment, even if the connection is not obvious to you.
Impact: All rating levels; particularly impacts residuals rating potential
Not bringing documentation of assistive device prescriptions or use
If you use a cane, walker, wheelchair, brace, or crutches but do not bring them or mention them, the examiner cannot document this on the DBQ. Assistive device use is a separately recorded finding that affects the overall functional assessment and can support Special Monthly Compensation.
Instead: Bring all prescribed assistive devices to the exam. If you have a prescription for any device, bring a copy. Use the device during the exam if it is part of your normal daily routine.
Impact: Functional limitation ratings; Special Monthly Compensation eligibility
Not reporting cognitive symptoms or minimizing them as normal aging
Cognitive impairment from a brain tumor or its treatment is a distinctly ratable neurological residual. Veterans frequently attribute memory loss, word-finding difficulties, or executive function deficits to aging or stress rather than the brain tumor. Examiners will only document what is reported.
Instead: Describe specific, recent examples of cognitive failures with dates and context. State explicitly: 'My doctor and I believe these cognitive symptoms are related to my brain tumor and/or its treatment.' Bring any prior neuropsychological testing results.
Impact: Cognitive impairment residuals; functional impairment narrative affecting overall rating
Failing to clarify whether active treatment is ongoing
The distinction between active disease (100%) and residuals phase is critical for DC 8003. If you are still in treatment or the tumor is still present, you are entitled to the 100% active disease rating. If the examiner does not confirm this clearly, the rating may be assigned prematurely at a lower residuals level.
Instead: State at the start of the exam whether you are currently in active treatment, in watchful waiting, or in a post-treatment residuals phase. Bring a letter from your treating oncologist or neurosurgeon confirming current status.
Impact: 100% active disease rating
Not describing the functional impact on work and daily activities
The CNS DBQ specifically asks about the impact of each neurological condition on the veteran's ability to work. VA raters use this narrative to support Total Disability Individual Unemployability (TDIU) claims and to substantiate higher combined ratings. Examiners who do not hear this information may leave the functional impact section blank or minimized.
Instead: Before the exam ends, proactively tell the examiner: 'I want to make sure the functional impact on my ability to work is fully documented.' Then describe specifically how your symptoms prevent you from maintaining full-time employment, including which job tasks are impossible and why.
Impact: TDIU eligibility; overall combined rating narrative
Prep Checklist
Before Your Exam
Day Of
During the Exam
After the Exam
Your Rights During a C&P Exam
- You have the right to have a VSO representative, accredited claims agent, or attorney present during your C&P examination.
- You have the right to record your C&P examination in states that permit one-party consent recording; notify the examiner before the exam begins.
- You have the right to request a copy of the completed DBQ after it is submitted to the VA Regional Office.
- You have the right to request a new or supplemental C&P examination if you believe the original exam was inadequate, incomplete, or inaccurate under 38 CFR 3.159(c)(4).
- You have the right to submit a rebuttal or personal statement if the DBQ does not accurately reflect your symptoms or functional limitations.
- You have the right to submit buddy statements (lay evidence) from family members, caregivers, or coworkers that corroborate your functional limitations under 38 CFR 3.303.
- You have the right to have all evidence of record-including private medical records, treatment notes, and imaging-reviewed by the examiner before the opinion is rendered.
- You have the right to request a fully favorable nexus opinion if there is a clear in-service event, diagnosis, and current disability; the benefit of the doubt standard (38 CFR 3.102) applies when evidence is in approximate balance.
- You have the right to appeal a C&P examiner's opinion that you believe is inadequate, negative, or not based on a thorough review of your medical history, including requesting a higher-level review or submitting a Notice of Disagreement.
- You have the right to concurrent ratings for all separately ratable residuals of your benign brain tumor (e.g., headaches, cognitive impairment, bowel/bladder dysfunction, sleep apnea) in addition to the primary DC 8003 rating.
- You have the right to request Total Disability Individual Unemployability (TDIU) if your service-connected neurological residuals prevent you from maintaining substantially gainful employment.
- You have the right to Special Monthly Compensation (SMC) if you have loss of use of a hand or foot, blindness, or require the regular aid and attendance of another person due to your neurological condition.
Related Conditions
- Malignant Brain Tumor DC 8002 covers malignant brain tumors under 38 CFR 4.124a. If a benign tumor later undergoes malignant transformation, re rating under DC 8002 may apply. VA policy concedes 100% for two years following cessation of treatment for malignant tumors.
- Epilepsy / Seizure Disorder Seizures are a common neurological residual of brain tumors and their treatment. Seizure disorder may be separately rated under DC 8910 (grand mal) or DC 8911 (petit mal) as a secondary condition to DC 8003, using the frequency based rating criteria under 38 CFR 4.124a.
- Migraine Headaches Chronic headaches secondary to a brain tumor or its treatment may be separately ratable under DC 8100 based on frequency of prostrating attacks with or without productive work loss. Headaches are a distinct ratable manifestation separate from the primary tumor rating.
- Hemiplegia or Hemiparesis Motor deficits resulting from a brain tumor may be rated under DC 8007 (hemiplegia) or analogous paralysis codes as residuals following the active disease phase of DC 8003. These are rated separately and combined using 38 CFR 4.25.
- Cognitive Impairment / TBI Residuals Cognitive residuals from a brain tumor may be evaluated analogously to TBI residuals under DC 8045. Neuropsychological testing may be required to document cognitive impairment severity for rating purposes.
- Sleep Apnea Sleep apnea may develop as a neurological sequela of a brain tumor affecting brainstem respiratory control centers or as a secondary effect of treatments. If service connected as secondary to DC 8003, it is separately ratable under DC 6847 at a minimum of 50% if requiring CPAP/BiPAP.
- Neurogenic Bladder Bladder dysfunction secondary to the neurological effects of a brain tumor is a ratable residual. Depending on severity, it may be rated under various codes including those for voiding dysfunction, urinary incontinence, and urinary retention requiring catheterization.
- Depression / Anxiety Secondary to Brain Tumor Mental health conditions developing secondary to the diagnosis, treatment, and functional limitations caused by a brain tumor are potentially service connected as secondary conditions under 38 CFR 3.310. These are rated under the General Rating Formula for Mental Disorders using DC 9434 or 9413.
- Dysphagia / Esophageal Disorders Swallowing difficulties from brainstem involvement or treatment effects are ratable neurological residuals. Severity ratings include daily medication requirement, esophageal stent placement, PEG tube placement, and aspiration risk, each carrying specific rating levels on the CNS DBQ.
- Hydrocephalus Hydrocephalus may develop as a direct complication of a benign brain tumor obstructing CSF pathways. It is listed as a separate diagnosable condition on the CNS DBQ and may be rated separately as a residual complication under DC 8045 or analogous codes.
Get Personalized C&P Exam Preparation
Upload your medical records for AI-powered prep that maps YOUR symptoms to the exact DBQ fields your examiner will evaluate.
This C&P exam preparation guide is for educational purposes only and does not constitute legal, medical, or claims advice. Always consult with a qualified Veterans Service Organization (VSO) representative or VA-accredited attorney for guidance specific to your claim. Never exaggerate, minimize, or fabricate symptoms during a C&P examination.